Drug Profile
ICN 3520
Alternative Names: Compound 3520; UricytinLatest Information Update: 16 Apr 2008
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA); University of Utah
- Developer National Cancer Institute (USA); Viratek
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 16 Apr 1997 No-Development-Reported for Cancer in USA (Unknown route)